JAK2 and graft versus host disease: Our results therefore suggest that the effect of JAK2/IL-6 targeting in GVHD therapy differs between patient subsets, but further studies are needed to clarify whether the clinical effects of IL-6 targeting therapy will also differ between patient subsets.